Skip to main content
PMC home page
American Journal of Human Genetics logoLink to American Journal of Human Genetics
. 1998 Jul;63(1):11–16. doi: 10.1086/301941

Pharmacogenetics of cancer therapy: getting personal.

E Y Krynetski 1, W E Evans 1
PMCID: PMC1377260  PMID: 9634537

Full Text

The Full Text of this article is available as a PDF (409.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chang T. K., Yu L., Goldstein J. A., Waxman D. J. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics. 1997 Jun;7(3):211–221. doi: 10.1097/00008571-199706000-00006. [DOI] [PubMed] [Google Scholar]
  2. Chocair P. R., Duley J. A., Simmonds H. A., Cameron J. S. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation. 1992 May;53(5):1051–1056. doi: 10.1097/00007890-199205000-00016. [DOI] [PubMed] [Google Scholar]
  3. Czerwinski M., Gibbs J. P., Slattery J. T. Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos. 1996 Sep;24(9):1015–1019. [PubMed] [Google Scholar]
  4. Diasio R. B., Beavers T. L., Carpenter J. T. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest. 1988 Jan;81(1):47–51. doi: 10.1172/JCI113308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Elion G. B. The purine path to chemotherapy. Science. 1989 Apr 7;244(4900):41–47. doi: 10.1126/science.2649979. [DOI] [PubMed] [Google Scholar]
  6. Evans W. E., Horner M., Chu Y. Q., Kalwinsky D., Roberts W. M. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr. 1991 Dec;119(6):985–989. doi: 10.1016/s0022-3476(05)83063-x. [DOI] [PubMed] [Google Scholar]
  7. Gonzalez F. J., Fernandez-Salguero P. Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency. Trends Pharmacol Sci. 1995 Oct;16(10):325–327. doi: 10.1016/s0165-6147(00)89065-3. [DOI] [PubMed] [Google Scholar]
  8. Grant D. M. Molecular genetics of the N-acetyltransferases. Pharmacogenetics. 1993 Feb;3(1):45–50. doi: 10.1097/00008571-199302000-00005. [DOI] [PubMed] [Google Scholar]
  9. Hartsough M. T., Steeg P. S. Nm23-H1: genetic alterations and expression patterns in tumor metastasis. Am J Hum Genet. 1998 Jul;63(1):6–10. doi: 10.1086/301942. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hollander A. A., van Saase J. L., Kootte A. M., van Dorp W. T., van Bockel H. J., van Es L. A., van der Woude F. J. Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet. 1995 Mar 11;345(8950):610–614. doi: 10.1016/s0140-6736(95)90520-0. [DOI] [PubMed] [Google Scholar]
  11. Iyer L., King C. D., Whitington P. F., Green M. D., Roy S. K., Tephly T. R., Coffman B. L., Ratain M. J. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 1998 Feb 15;101(4):847–854. doi: 10.1172/JCI915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Krynetski E. Y., Schuetz J. D., Galpin A. J., Pui C. H., Relling M. V., Evans W. E. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):949–953. doi: 10.1073/pnas.92.4.949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Krynetski E. Y., Tai H. L., Yates C. R., Fessing M. Y., Loennechen T., Schuetz J. D., Relling M. V., Evans W. E. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics. 1996 Aug;6(4):279–290. doi: 10.1097/00008571-199608000-00001. [DOI] [PubMed] [Google Scholar]
  14. Lennard L., Keen D., Lilleyman J. S. Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations. Clin Pharmacol Ther. 1986 Sep;40(3):287–292. doi: 10.1038/clpt.1986.178. [DOI] [PubMed] [Google Scholar]
  15. Lennard L., Lilleyman J. S., Van Loon J., Weinshilboum R. M. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 1990 Jul 28;336(8709):225–229. doi: 10.1016/0140-6736(90)91745-v. [DOI] [PubMed] [Google Scholar]
  16. Lennard L., Lilleyman J. S. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol. 1989 Dec;7(12):1816–1823. doi: 10.1200/JCO.1989.7.12.1816. [DOI] [PubMed] [Google Scholar]
  17. McLeod H. L., Lin J. S., Scott E. P., Pui C. H., Evans W. E. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther. 1994 Jan;55(1):15–20. doi: 10.1038/clpt.1994.4. [DOI] [PubMed] [Google Scholar]
  18. McLeod H. L., Miller D. R., Evans W. E. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet. 1993 May 1;341(8853):1151–1151. doi: 10.1016/0140-6736(93)93168-z. [DOI] [PubMed] [Google Scholar]
  19. McLeod H. L., Relling M. V., Liu Q., Pui C. H., Evans W. E. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood. 1995 Apr 1;85(7):1897–1902. [PubMed] [Google Scholar]
  20. Meyer U. A., Zanger U. M. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol. 1997;37:269–296. doi: 10.1146/annurev.pharmtox.37.1.269. [DOI] [PubMed] [Google Scholar]
  21. Nebert D. W., McKinnon R. A., Puga A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol. 1996 Apr;15(4):273–280. doi: 10.1089/dna.1996.15.273. [DOI] [PubMed] [Google Scholar]
  22. Nebert D. W. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am J Hum Genet. 1997 Feb;60(2):265–271. [PMC free article] [PubMed] [Google Scholar]
  23. Otterness D., Szumlanski C., Lennard L., Klemetsdal B., Aarbakke J., Park-Hah J. O., Iven H., Schmiegelow K., Branum E., O'Brien J. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther. 1997 Jul;62(1):60–73. doi: 10.1016/S0009-9236(97)90152-1. [DOI] [PubMed] [Google Scholar]
  24. Ratain M. J., Mick R., Berezin F., Janisch L., Schilsky R. L., Williams S. F., Smiddy J. Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther. 1991 Nov;50(5 Pt 1):573–579. doi: 10.1038/clpt.1991.183. [DOI] [PubMed] [Google Scholar]
  25. Schütz E., Gummert J., Mohr F., Oellerich M. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet. 1993 Feb 13;341(8842):436–436. doi: 10.1016/0140-6736(93)93028-y. [DOI] [PubMed] [Google Scholar]
  26. Szumlanski C. L., Honchel R., Scott M. C., Weinshilboum R. M. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics. 1992 Aug;2(4):148–159. [PubMed] [Google Scholar]
  27. Szumlanski C., Otterness D., Her C., Lee D., Brandriff B., Kelsell D., Spurr N., Lennard L., Wieben E., Weinshilboum R. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol. 1996 Jan;15(1):17–30. doi: 10.1089/dna.1996.15.17. [DOI] [PubMed] [Google Scholar]
  28. Tai H. L., Krynetski E. Y., Schuetz E. G., Yanishevski Y., Evans W. E. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6444–6449. doi: 10.1073/pnas.94.12.6444. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Tai H. L., Krynetski E. Y., Yates C. R., Loennechen T., Fessing M. Y., Krynetskaia N. F., Evans W. E. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet. 1996 Apr;58(4):694–702. [PMC free article] [PubMed] [Google Scholar]
  30. Van Loon J. A., Szumlanski C. L., Weinshilboum R. M. Human kidney thiopurine methyltransferase. Photoaffinity labeling with S-adenosyl-L-methionine. Biochem Pharmacol. 1992 Aug 18;44(4):775–785. doi: 10.1016/0006-2952(92)90416-g. [DOI] [PubMed] [Google Scholar]
  31. Van Loon J. A., Weinshilboum R. M. Thiopurine methyltransferase biochemical genetics: human lymphocyte activity. Biochem Genet. 1982 Aug;20(7-8):637–658. doi: 10.1007/BF00483962. [DOI] [PubMed] [Google Scholar]
  32. Wei X., McLeod H. L., McMurrough J., Gonzalez F. J., Fernandez-Salguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest. 1996 Aug 1;98(3):610–615. doi: 10.1172/JCI118830. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Weinshilboum R. M., Raymond F. A., Pazmiño P. A. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta. 1978 May 2;85(3):323–333. doi: 10.1016/0009-8981(78)90311-x. [DOI] [PubMed] [Google Scholar]
  34. Weinshilboum R. M., Sladek S. L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980 Sep;32(5):651–662. [PMC free article] [PubMed] [Google Scholar]
  35. Woodson L. C., Dunnette J. H., Weinshilboum R. M. Pharmacogenetics of human thiopurine methyltransferase: kidney-erythrocyte correlation and immunotitration studies. J Pharmacol Exp Ther. 1982 Jul;222(1):174–181. [PubMed] [Google Scholar]
  36. Yates C. R., Krynetski E. Y., Loennechen T., Fessing M. Y., Tai H. L., Pui C. H., Relling M. V., Evans W. E. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med. 1997 Apr 15;126(8):608–614. doi: 10.7326/0003-4819-126-8-199704150-00003. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Human Genetics are provided here courtesy of American Society of Human Genetics

RESOURCES